Amyris, Inc. (NASDAQ:AMRS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Amyris, Inc. (NASDAQ:AMRS) have earned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.39.

AMRS has been the subject of several research reports. Oppenheimer boosted their price objective on shares of Amyris from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Friday, August 6th. Zacks Investment Research raised shares of Amyris from a “sell” rating to a “hold” rating in a research report on Friday, August 6th. HC Wainwright decreased their price target on shares of Amyris from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, August 6th. Finally, Roth Capital decreased their price target on shares of Amyris from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 6th.

Shares of NASDAQ AMRS traded up $0.83 during trading on Friday, hitting $13.44. 150,424 shares of the company traded hands, compared to its average volume of 3,935,059. Amyris has a 1 year low of $1.88 and a 1 year high of $23.42. The company has a 50-day moving average price of $13.67 and a 200-day moving average price of $14.61. The firm has a market capitalization of $4.00 billion, a P/E ratio of -6.46 and a beta of 1.13.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). The firm had revenue of $52.32 million for the quarter, compared to the consensus estimate of $53.73 million. On average, research analysts predict that Amyris will post -1.19 EPS for the current fiscal year.

In related news, insider Nicole Kelsey sold 3,483 shares of the stock in a transaction dated Thursday, September 2nd. The shares were sold at an average price of $14.86, for a total transaction of $51,757.38. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Hermanus Kieftenbeld sold 24,380 shares of the stock in a transaction dated Thursday, September 2nd. The stock was sold at an average price of $14.86, for a total transaction of $362,286.80. The disclosure for this sale can be found here. Insiders sold a total of 46,630 shares of company stock worth $692,922 in the last quarter. 36.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Amyris by 90.9% in the 2nd quarter. BlackRock Inc. now owns 22,829,395 shares of the biotechnology company’s stock worth $373,717,000 after purchasing an additional 10,873,530 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Amyris by 82.0% in the second quarter. Vanguard Group Inc. now owns 17,376,918 shares of the biotechnology company’s stock valued at $284,461,000 after acquiring an additional 7,827,670 shares in the last quarter. Pinnacle Associates Ltd. boosted its holdings in shares of Amyris by 15.8% in the second quarter. Pinnacle Associates Ltd. now owns 4,660,308 shares of the biotechnology company’s stock valued at $76,289,000 after acquiring an additional 636,216 shares in the last quarter. Lord Abbett & CO. LLC boosted its holdings in shares of Amyris by 27.5% in the second quarter. Lord Abbett & CO. LLC now owns 3,364,008 shares of the biotechnology company’s stock valued at $55,069,000 after acquiring an additional 726,033 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Amyris by 51.4% in the second quarter. State Street Corp now owns 3,361,202 shares of the biotechnology company’s stock valued at $55,023,000 after acquiring an additional 1,141,422 shares in the last quarter. Hedge funds and other institutional investors own 44.16% of the company’s stock.

About Amyris

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Further Reading: How does equity income fit into an investing strategy?

Analyst Recommendations for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.